Business / Finance

RSS

Healthspring fourth quarter revenues increase 29.4% to $50.9 million

HealthSpring, Inc. today announced its results for the fourth quarter and year ended December 31, 2010. HealthSpring's 2010 results include one month's contribution from the operations of Bravo Health, Inc., which was acquired by HealthSpring on November 30, 2010, and transaction expenses related to the acquisition.

18 Feb 2011

Safeguard Scientifics' 2010 partner company aggregate revenue exceeds $400 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for 2010 exceeded $400 million, beating previously issued guidance of $360 million to $385 million.

18 Feb 2011

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

18 Feb 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, securities in a registered offering to a single life sciences institutional investor. The Company may use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.

18 Feb 2011

NHI fourth quarter normalized FFO improves to $0.72 per basic and diluted common share

National Health Investors, Inc. announced today its normalized Funds From Operations ("FFO") and net income for the three months and year ended December 31, 2010.

18 Feb 2011

3M announces acquisition of Hybrivet Systems

3M announced today it has acquired Hybrivet Systems Inc., a leading provider of instant-read products to detect lead and other contaminants and toxins. Terms of the transaction were not disclosed.

17 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Spectranetics fourth quarter revenues decrease 1% to $29.3 million

Spectranetics Corporation today reported financial results for the quarter and full year ended December 31, 2010.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Urologix granted additional cure period to regain NASDAQ compliance

Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,

17 Feb 2011

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

The European Medicines Agency has published a concept paper on storage conditions during transport. The goal is to create new Good Distribution Practice and GMP guidance and may lead to the need to revise the guideline on declaration of storage conditions.

From IQPC Ltd 17 Feb 2011

Omega fourth quarter net income decreases to $5.0 million

Omega Healthcare Investors, Inc. today announced its results of operations for the quarter and fiscal year ended December 31, 2010. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three months ended December 31, 2010 of $28.4 million or $0.29 per common share.

17 Feb 2011

Celgene board authorizes additional $1 billion share repurchase

Celgene Corporation today announced that the company's Board of Directors has authorized the repurchase of up to an additional $1 billion of the Company's common stock through December 2012.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

Orexo fourth quarter net revenues increase to MSEK 109.1

Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.

16 Feb 2011